Welcome to our dedicated page for Traws Pharma news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Traws Pharma Inc (ONTX) is a clinical-stage biopharmaceutical company advancing novel cancer therapies through targeted small molecule drug development. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress and corporate developments.
Access official press releases, clinical trial milestones, and financial filings in one centralized location. Our curated collection includes updates on translational research breakthroughs, regulatory submissions, and strategic partnerships relevant to ONTX's oncology pipeline.
Key content categories include clinical program advancements, intellectual property developments, and financial performance reports. All materials are sourced directly from company communications and verified financial disclosures to ensure accuracy.
Bookmark this page for streamlined tracking of Traws Pharma's progress in developing precision therapies that aim to improve cancer treatment outcomes. Check regularly for updates on their proprietary drug discovery platform and pipeline candidates moving through clinical evaluation.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced a definitive purchase agreement for a registered direct offering of 19,550,562 shares at $0.445 per share, potentially raising $8.7 million. The offering, closing around January 11, 2021, will primarily support working capital and general corporate purposes. Investors include Lincoln Park Capital and Sio Capital. The offering is made under an effective SEC registration statement, with proceeds aimed at advancing Onconova's clinical development.
Onconova Therapeutics (NASDAQ: ONTX) has received FDA approval for a Phase 1 trial of its multi-kinase inhibitor ON 123300, aimed at treating HR+ HER2- metastatic breast cancer and other tumors. The trial, expected to begin in the first half of 2021, will assess the safety and pharmacokinetics of ON 123300, starting with an oral dose of 40 mg daily. The company anticipates enrolling patients resistant to existing treatments. This innovative drug could also show promise for other cancers, as indicated by its preclinical studies.
Onconova Therapeutics has filed an Investigational New Drug application with the FDA for ON 123300, a first-in-class multi-kinase inhibitor aimed at treating advanced cancers, notably HR+ HER 2- metastatic breast cancer resistant to CDK4/6 inhibitors. U.S. Phase 1 trial enrollment is set to begin in the first half of 2021, complementing a concurrent study in China. The dual studies aim to gather crucial data for future phases. ON 123300 shows promise in targeting various cancers, including mantle cell lymphoma and glioblastoma, based on preclinical results.
Onconova Therapeutics reported Q3 2020 results and announced the clinical entry of ON 123300, a multi-kinase inhibitor, in collaboration with HanX Biopharmaceuticals. The Phase 1 study aims to explore ON 123300's efficacy in advanced solid tumors. Concurrently, a Phase 1 study combining oral rigosertib and nivolumab for K-RAS mutated non-small cell lung cancer is ongoing. The company holds $24.2 million in cash, sufficient to fund operations into Q1 2022. Net loss increased to $6.2 million, reflecting higher R&D and G&A expenses compared to Q3 2019.
Onconova Therapeutics (NASDAQ: ONTX) will release its third quarter financial results on November 12, 2020, after market close. A conference call is scheduled for 4:30 p.m. ET that same day to discuss the results and pipeline updates. The company's novel CDK4/6 + ARK5 inhibitor, ON 123300, is in a Phase 1 trial in China, with an IND filing expected in Q4 2020. Additionally, the RAS pathway inhibitor, oral rigosertib, is in another Phase 1 study for KRAS+ lung adenocarcinoma.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced a presentation by CEO Dr. Steven M. Fruchtman at the 2020 BIO Investor Forum Digital event from October 13-15. The company aims to update participants on its cancer treatment developments. Additionally, 1x1 meetings will be available through the Bio Partnering system. Event attendees can access the presentation on demand starting October 15 at this link. Onconova is developing innovative cancer therapies, including the CDK4/6 + ARK5 inhibitor ON 123300 and the RAS pathway inhibitor rigosertib.
Onconova Therapeutics (NASDAQ: ONTX) announced the initiation of a Phase 1 clinical trial for ON 123300 in China, developed in partnership with HanX Biopharmaceuticals. This dual inhibitor targets CDK4/6 and ARK5, aimed at enhancing the efficacy of existing cancer treatments while minimizing side effects. The company plans to file a US IND by the end of 2020 and expects to commence a US Phase 1 study in refractory solid tumors by Q1 2021. This strategic move is part of Onconova's broader efforts to advance its pipeline of anti-cancer agents.
Onconova Therapeutics, Inc. (NASDAQ: ONTX), focused on cancer treatment, announced participation in key upcoming events. The company will engage in the Marcus Evans Healthcare Investment Webinar on September 10, discussing ESG investment opportunities amidst COVID-19. They will also present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 and at the 2nd Annual RAS-Targeted Drug Development Conference on September 16, showcasing their research on rigosertib, a unique RAS antagonist. For additional details, visit onconova.com.
Onconova Therapeutics announces James J. Marino as the new Chairman of the Board of Directors. Mr. Marino, a seasoned professional with over 30 years of life sciences experience, has been a board member since July 2015. His leadership comes during a critical phase for Onconova, as the company advances clinical development plans for its cancer treatments, including oral rigosertib and ON 123300. The press release also mentions the resignation of board members Michael Hoffman and E. Premkumar Reddy, who contributed to the company’s foundation and key pipeline assets.
Onconova Therapeutics announced that its Phase 3 INSPIRE trial of IV rigosertib in higher-risk myelodysplastic syndromes (HR-MDS) failed to meet its primary endpoint of improved overall survival compared to physician's choice. The trial showed an overall survival of 6.4 months for rigosertib against 6.3 months for the control (p=0.33). Despite this setback, Onconova will shift focus to its pipeline, including oral rigosertib and ON 123300, both targeting key cancer pathways. A conference call is scheduled for later today to discuss these developments.
